Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump

Beta Bionics received FDA clearance for its Mint tubeless insulin patch pump, planning a U.S. launch in early 2027. The company expects 40% of insured Americans to have pharmacy coverage at launch, rising to 50% within a year. Beta Bionics lowered its 2026 revenue forecast to $121M-$126M, citing potential deferrals as customers wait for Mint. The pump will compete with Insulet's dominant patch pump and Medtronic's upcoming submission.

Beta Bionics (BBNX) priced a public offering of 7.65 million shares at $17.25 each and pre-funded warrants for 1.04 million shares at $17.2499, raising $150 million. The deal, expected to close by September 17, 2026, includes a 30-day over-allotment option. Latham & Watkins advised the underwriters.

Beta Bionics (BBNX) stock rose 5.93% to $20.37 after announcing a public offering expected to generate $150M in gross proceeds. The offering includes 7.65M common shares and warrants. Proceeds will fund corporate purposes, including commercialization and R&D.

Beta Bionics (BBNX) priced a $150 million public offering of 7.65 million shares at $17.25 each, plus warrants. Proceeds will fund Mint commercialization, expansion, and R&D. The offering is expected to close by September 17, 2026. BBNX shares fell 6.6% overnight.

Beta Bionics (BBNX) shares fell 5.4% in after-hours trading to $18.20 after announcing a $125M stock offering, potentially diluting shares. The company also reduced its 2026 revenue guidance by $10M. UBS raised its price target to $25, citing FDA clearance for the Mint patch pump, but the stock still declined.

Beta Bionics Inc (BBNX) shares fell 6.4% after announcing a $125M common stock offering, with an option for $18.75M more. Proceeds will fund corporate purposes, including Mint product commercialization and R&D. J.P. Morgan and others are joint book-running managers. Completion and terms are uncertain.